Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients

Journal of Clinical Psychopharmacology

Volumn 26, Issue 4, 2006, Pages 367-372

  Yin, Ophelia Q P ^a   Wing, Yun Kowk ^a   Cheung, Yuet ^a   Wang, Zhi Jun ^a   Lam, Siu Ling ^a   Chiu, Helen F K ^a   Chow, Moses S S ^a  

^a Chinese University of Hong Kong   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2C19; NORCITALOPRAM;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM DISEASE; CHINESE; DEPRESSIVE PSYCHOSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD DISORDER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RATING SCALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEXUAL DYSFUNCTION; TORONTO SIDE EFFECTS SCALE;

ADMINISTRATION, ORAL; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MOOD DISORDERS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 33746906715     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000227355.54074.14     Document Type: Article

References (27)

1. Milne RJ, Goa KL. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991;41:450-477.
2. Hyttel J. Citalopram-pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6:277-295.
3. Leinonen E, Lepola U, Koponen H, et al. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit. 1996;18:111-117.
4. Fredricson Overo K. Kinetics of citalopram in man; plasma levels in patients. Prog Neuropsychopharmacology Biol Psychiatry. 1982;6:311-318.
5. Sindrup SH, Brosen K, Hansen MG, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit. 1993;15:11-17.
6. Yu B-N, Chen G-L, He N, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos. 2003;31:1255-1259.
7. Herrlin K, Yasui-Furukori N, Tybring G, et al. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol. 2003;56:415-421.
8. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913-958.
9. http://medicine.iupui.edu/flockhart. Accessed February 15, 2005.
10. Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol. 1995;10(suppl 1):15-21.
11. Gutierrez MM, Abramowitz W. Pharmacokinetic comparison of oral solution and tablet formulations of citalopram: a single-dose, randomized, crossover study. Clin Ther. 2000;22:1525-1532.
12. Sidhu J, Priskorn M, Poulsen M, et al. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality. 1997:686-692.
13. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry. 2002;47:174-180.
14. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419-15422.
15. de Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594-598.
16. US Department of Health and Human Services Food and Drug Administration, Guidance for Industry: Bioanalytical method validation. US Department of Health and Human Services, Beltsville, MD; 2001.
17. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther. 1997;280:927-933.
18. Olesen OV, Linnet K. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology. 1999;59:298-309.
19. Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochromeinhibitory effects. Biol Psychiatry. 1999;46:839-849.
20. Gutierrez M, Abramowitz W. Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram. Pharmacotherapy. 2001;21:163-168.
21. Nolting A, Abramowitz W. Lack of interaction between citalopram and the CYP3A4 substrate triazolam. Pharmacotherapy. 2000;20:750-755.
22. Hsieh KP, Lin YY, Cheng CL, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos. 2001;29:268-273.
23. Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;299:825-831.
24. Bies RR, Feng Y, Lotrich FE, et al. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol. 2004;44:1352-1359.
25. Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit. 2003;25:183-191.
26. Overo KF, Toft B, Christophersen L, et al. Kinetics of citalopram in elderly patients. Psychopharmacology. 1985;86:253-257.
27. Leinonen E, Lepola U, Koponen H, et al. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit. 1996;18:111-117.